344 related articles for article (PubMed ID: 30338457)
1. Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma.
Hu B; Jacobs R; Ghosh N
Curr Hematol Malig Rep; 2018 Dec; 13(6):543-554. PubMed ID: 30338457
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
3. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.
Merryman RW; Armand P; Wright KT; Rodig SJ
Blood Adv; 2017 Dec; 1(26):2643-2654. PubMed ID: 29296917
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
7. [Checkpoint inhibitors in Hodgkin lymphoma].
Sasse S; Momotow J; Engert A
Internist (Berl); 2020 Jul; 61(7):660-668. PubMed ID: 32462248
[TBL] [Abstract][Full Text] [Related]
8. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
[TBL] [Abstract][Full Text] [Related]
9. Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas.
Dilly-Feldis M; Aladjidi N; Refait JK; Parrens M; Ducassou S; Rullier A
Pediatr Blood Cancer; 2019 May; 66(5):e27571. PubMed ID: 30637917
[TBL] [Abstract][Full Text] [Related]
10. Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.
Hradska K; Kascak M; Hajek R; Jelinek T
Expert Rev Hematol; 2020 Apr; 13(4):375-392. PubMed ID: 32116068
[No Abstract] [Full Text] [Related]
11. Pembrolizumab for the treatment of diffuse large B-cell lymphoma.
Sheikh S; Kuruvilla J
Expert Opin Biol Ther; 2019 Nov; 19(11):1119-1126. PubMed ID: 31456438
[No Abstract] [Full Text] [Related]
12. Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas.
Kim SJ; Hyeon J; Cho I; Ko YH; Kim WS
Cancer Res Treat; 2019 Apr; 51(2):611-622. PubMed ID: 30025443
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives.
Lin N; Song Y; Zhu J
Chin J Cancer Res; 2020 Jun; 32(3):303-318. PubMed ID: 32694896
[TBL] [Abstract][Full Text] [Related]
14. Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition.
De Re V; Caggiari L; Repetto O; Mussolin L; Mascarin M
J Clin Med; 2019 Oct; 8(10):. PubMed ID: 31581738
[No Abstract] [Full Text] [Related]
15. PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma.
Tobin JWD; Bednarska K; Campbell A; Keane C
Cells; 2021 May; 10(5):. PubMed ID: 34068762
[TBL] [Abstract][Full Text] [Related]
16. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
Xu-Monette ZY; Zhou J; Young KH
Blood; 2018 Jan; 131(1):68-83. PubMed ID: 29118007
[TBL] [Abstract][Full Text] [Related]
17. Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.
Chang A; Schlafer D; Flowers CR; Allen PB
Expert Opin Investig Drugs; 2018 Jan; 27(1):55-70. PubMed ID: 29228840
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibition in classical hodgkin lymphoma.
Pezeshki PS; Eskian M; Hamblin MR; Rezaei N
Expert Rev Anticancer Ther; 2021 Sep; 21(9):1003-1016. PubMed ID: 33857395
[No Abstract] [Full Text] [Related]
19. Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.
Falchi L
Curr Hematol Malig Rep; 2017 Oct; 12(5):484-494. PubMed ID: 28822058
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
